It’s a lucrative game: in general, after every one of these dramatic announcements, you will see their share prices go up. It’s about money, and creating new markets secured through government ‘public health’ policies and funding.
In reality, the public’s health is the least of their concern…
Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine which targets both the original as well as the BA.2 Omicron subvariant.
Pfizer said the vaccine is in an initial proof-of-concept study to gather more data. (https://bit.ly/3veWPKn)
Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of the circulating coronavirus variants in the United States for the week ended July 23. read more
The U.S. Food and Drug Administration last month asked vaccine manufacturers to target BA.4 and BA.5, the two currently dominant Omicron subvariants, for a potential fall season booster dose.
Apparently, the US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
The U.S. Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.
If authorized, the changes would mark the first major retooling of COVID vaccines, but also could slow their rollout as the FDA has recommended a design somewhat different from what the companies had already tested and started producing.
The FDA will not require new studies testing the BA.4/BA.5 shots in humans to be completed for authorization, a top agency official told Reuters, similar to how annual changes to flu vaccines are handled.
SEE MORE VACCINE NEWS AT: 21st Century Wire Vaccine Files
PLEASE HELP SUPPORT OUR INDEPENDENT MEDIA PLATFORM HERE